PFE

Pfizer
D

PFE

Arincen59/100B

Pfizer cash on hand 1985–2026

Pfizer had 14.27B USD in cash and short-term investments on 27 September 2026, down 4.8% on a year before. At the end of fiscal year 2025 it had 13.60B USD.

Last updated 3 Nov 2026 · Next report 2 Feb 2027

Cash on hand

Growth

Fiscal yearPeriod endingCash on handGrowthTotal debtNet cash
Latest quarter27 Sept 202614.27B-4.75%62.67B-48.40B
FY202531 Dec 202513.60B-33.60%67.42B-53.82B
FY202431 Dec 202420.48B+61.36%66.99B-46.52B
FY202331 Dec 202312.69B-44.18%70.85B-58.16B
FY202231 Dec 202222.73B-26.83%34.86B-12.13B
FY202131 Dec 202131.07B+154.18%37.00B-5.93B
FY202031 Dec 202012.22B+26.72%38.27B-26.05B
FY201931 Dec 20199.65B-48.78%50.84B-41.19B
FY201831 Dec 201818.83B-5.80%41.75B-22.91B
FY201731 Dec 201719.99B+12.00%42.61B-22.61B
FY201631 Dec 201617.85B-23.36%41.06B-23.21B
FY201531 Dec 201523.29B-35.52%38.90B-15.61B
FY201431 Dec 201436.12B+11.46%36.68B-560.00M
FY201331 Dec 201332.41B+0.02%36.49B-4.08B
FY201231 Dec 201232.40B+22.72%37.46B-5.06B
FY201131 Dec 201126.40B-5.75%38.94B-12.54B
FY201031 Dec 201028.01B+7.87%44.03B-16.02B
FY200931 Dec 200925.97B+9.43%48.66B-22.69B
FY200831 Dec 200823.73B-6.85%17.28B6.45B
FY200731 Dec 200725.48B-8.08%13.14B12.34B
FY200631 Dec 200627.71B+24.69%7.98B19.73B
FY200531 Dec 200522.23B+11.73%17.94B4.29B
FY200431 Dec 200419.89B+66.44%18.55B1.35B
FY200331 Dec 200311.95B-4.77%14.57B-2.62B
FY200231 Dec 200212.55B+45.69%11.81B742.00M
FY200131 Dec 20018.62B+25.53%8.87B-257.00M
FY200031 Dec 20006.86B+13.23%5.41B1.45B
FY199931 Dec 19996.06B+290.53%7.07B-1.01B
FY199831 Dec 19981.55B+76.97%3.26B-1.70B
FY199731 Dec 1997877.00M-23.74%2.98B-2.10B
FY199631 Dec 19961.15B+185.15%2.92B-1.77B
FY199531 Dec 1995403.30M-72.35%2.87B-2.47B
FY199431 Dec 19941.46B+99.96%2.82B-1.37B
FY199331 Dec 1993729.40M-41.98%1.75B-1.02B
FY199231 Dec 19921.26B-4.59%1.82B-566.50M
FY199131 Dec 19911.32B+51.40%2.09B-770.10M
FY199031 Dec 1990870.30M+5.44%1.69B-822.30M
FY198931 Dec 1989825.40M+2.22%1.72B-891.50M
FY198831 Dec 1988807.50M-21.69%1.19B-387.10M
FY198731 Dec 19871.03B+158.68%963.80M67.30M
FY198631 Dec 1986398.60M-3.39%556.70M-158.10M
FY198531 Dec 1985412.60M—509.40M-96.80M

Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Stock buybacks,Balance sheet

Common questions about Pfizer's cash

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.